{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=N-Acetyl+Cysteine+%28NAC%29&page=7",
    "query": {
      "intervention": "N-Acetyl Cysteine (NAC)",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 229,
    "total_pages": 23,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=N-Acetyl+Cysteine+%28NAC%29&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=N-Acetyl+Cysteine+%28NAC%29&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-14T04:54:43.311Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01251315",
      "title": "The Effects of a Glutathione Precursor (FT061452),on Serum and Intracellular Glutathione Levels",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Oxidative Stress"
      ],
      "interventions": [
        {
          "name": "Placebo low dose",
          "type": "DRUG"
        },
        {
          "name": "N Acetyl cysteine, 600mg (low dose)",
          "type": "DRUG"
        },
        {
          "name": "Proimmune 200 (FT061452) 3000mg low dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo (high dose)",
          "type": "DRUG"
        },
        {
          "name": "N Acetyl cysteine, 1200mg (high dose)",
          "type": "DRUG"
        },
        {
          "name": "FT061452, 6000mg high dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Charles Drew University of Medicine and Science",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "30 Years to 65 Years"
      },
      "enrollment_count": 24,
      "start_date": "2010-12",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2014-04-14",
      "last_synced_at": "2026-10-14T04:54:43.311Z",
      "location_count": 1,
      "location_summary": "Los Angeles, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01251315"
    },
    {
      "nct_id": "NCT06083480",
      "title": "Reducing Perioperative Oxidative Stress to Prevent Postoperative Chronic Pain Following Total Knee Arthroplasty",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Osteoarthritis, Knee",
        "Total Knee Arthroplasty",
        "Chronic Postsurgical Pain"
      ],
      "interventions": [
        {
          "name": "GlyNAC (combination of glycine and n-acetylcysteine)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 148,
      "start_date": "2024-12-06",
      "completion_date": "2029-03",
      "has_results": false,
      "last_update_posted_date": "2025-12-11",
      "last_synced_at": "2026-10-14T04:54:43.311Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06083480"
    },
    {
      "nct_id": "NCT01172288",
      "title": "N-acetylcysteine (NAC) for Children With Tourette Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tourettes Syndrome",
        "Tic"
      ],
      "interventions": [
        {
          "name": "N-Acetylcysteine (NAC)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Yale University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "8 Years to 17 Years"
      },
      "enrollment_count": 31,
      "start_date": "2010-07",
      "completion_date": "2014-01",
      "has_results": true,
      "last_update_posted_date": "2017-02-10",
      "last_synced_at": "2026-10-14T04:54:43.311Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01172288"
    },
    {
      "nct_id": "NCT02737358",
      "title": "N-acetylcysteine for Tobacco Use Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Nicotine Dependence",
        "Smoking"
      ],
      "interventions": [
        {
          "name": "N-acetylcysteine (NAC)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 114,
      "start_date": "2016-08-30",
      "completion_date": "2019-10-10",
      "has_results": true,
      "last_update_posted_date": "2020-08-17",
      "last_synced_at": "2026-10-14T04:54:43.311Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02737358"
    },
    {
      "nct_id": "NCT02123511",
      "title": "Acetylcysteine Rinse in Reducing Saliva Thickness and Mucositis in Patients With Head and Neck Cancer Undergoing Radiation Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mucositis",
        "Oral Complications",
        "Recurrent Adenoid Cystic Carcinoma of the Oral Cavity",
        "Recurrent Basal Cell Carcinoma of the Lip",
        "Recurrent Lymphoepithelioma of the Nasopharynx",
        "Recurrent Lymphoepithelioma of the Oropharynx",
        "Recurrent Mucoepidermoid Carcinoma of the Oral Cavity",
        "Recurrent Salivary Gland Cancer",
        "Recurrent Squamous Cell Carcinoma of the Larynx",
        "Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Recurrent Squamous Cell Carcinoma of the Nasopharynx",
        "Recurrent Squamous Cell Carcinoma of the Oropharynx",
        "Recurrent Verrucous Carcinoma of the Larynx",
        "Recurrent Verrucous Carcinoma of the Oral Cavity",
        "Stage I Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage I Basal Cell Carcinoma of the Lip",
        "Stage I Lymphoepithelioma of the Nasopharynx",
        "Stage I Lymphoepithelioma of the Oropharynx",
        "Stage I Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage I Salivary Gland Cancer",
        "Stage I Squamous Cell Carcinoma of the Larynx",
        "Stage I Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage I Squamous Cell Carcinoma of the Nasopharynx",
        "Stage I Squamous Cell Carcinoma of the Oropharynx",
        "Stage I Verrucous Carcinoma of the Larynx",
        "Stage I Verrucous Carcinoma of the Oral Cavity",
        "Stage II Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage II Basal Cell Carcinoma of the Lip",
        "Stage II Lymphoepithelioma of the Nasopharynx",
        "Stage II Lymphoepithelioma of the Oropharynx",
        "Stage II Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage II Salivary Gland Cancer",
        "Stage II Squamous Cell Carcinoma of the Larynx",
        "Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage II Squamous Cell Carcinoma of the Nasopharynx",
        "Stage II Squamous Cell Carcinoma of the Oropharynx",
        "Stage II Verrucous Carcinoma of the Larynx",
        "Stage II Verrucous Carcinoma of the Oral Cavity",
        "Stage III Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage III Basal Cell Carcinoma of the Lip",
        "Stage III Lymphoepithelioma of the Nasopharynx",
        "Stage III Lymphoepithelioma of the Oropharynx",
        "Stage III Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage III Salivary Gland Cancer",
        "Stage III Squamous Cell Carcinoma of the Larynx",
        "Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage III Squamous Cell Carcinoma of the Nasopharynx",
        "Stage III Squamous Cell Carcinoma of the Oropharynx",
        "Stage III Verrucous Carcinoma of the Larynx",
        "Stage III Verrucous Carcinoma of the Oral Cavity",
        "Stage IV Lymphoepithelioma of the Nasopharynx",
        "Stage IV Squamous Cell Carcinoma of the Nasopharynx",
        "Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage IVA Basal Cell Carcinoma of the Lip",
        "Stage IVA Lymphoepithelioma of the Oropharynx",
        "Stage IVA Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage IVA Salivary Gland Cancer",
        "Stage IVA Squamous Cell Carcinoma of the Larynx",
        "Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IVA Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVA Verrucous Carcinoma of the Larynx",
        "Stage IVA Verrucous Carcinoma of the Oral Cavity",
        "Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage IVB Basal Cell Carcinoma of the Lip",
        "Stage IVB Lymphoepithelioma of the Oropharynx",
        "Stage IVB Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage IVB Salivary Gland Cancer",
        "Stage IVB Squamous Cell Carcinoma of the Larynx",
        "Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IVB Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVB Verrucous Carcinoma of the Larynx",
        "Stage IVB Verrucous Carcinoma of the Oral Cavity",
        "Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity",
        "Stage IVC Basal Cell Carcinoma of the Lip",
        "Stage IVC Lymphoepithelioma of the Oropharynx",
        "Stage IVC Mucoepidermoid Carcinoma of the Oral Cavity",
        "Stage IVC Salivary Gland Cancer",
        "Stage IVC Squamous Cell Carcinoma of the Larynx",
        "Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity",
        "Stage IVC Squamous Cell Carcinoma of the Oropharynx",
        "Stage IVC Verrucous Carcinoma of the Larynx",
        "Stage IVC Verrucous Carcinoma of the Oral Cavity",
        "Tongue Cancer"
      ],
      "interventions": [
        {
          "name": "acetylcysteine",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        },
        {
          "name": "quality-of-life assessment",
          "type": "OTHER"
        },
        {
          "name": "questionnaire administration",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2014-04",
      "completion_date": "2018-07-02",
      "has_results": true,
      "last_update_posted_date": "2019-04-30",
      "last_synced_at": "2026-10-14T04:54:43.311Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Rochester, Minnesota • Syracuse, New York + 2 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Syracuse",
          "state": "New York"
        },
        {
          "city": "Bismarck",
          "state": "North Dakota"
        },
        {
          "city": "Grand Forks",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02123511"
    },
    {
      "nct_id": "NCT01386645",
      "title": "Effect of Dietary Glycemic Index on Beta-cell Function",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Impaired Glucose Tolerance",
        "Oxidative Stress",
        "Prediabetes",
        "Impaired Fasting Glucose"
      ],
      "interventions": [
        {
          "name": "low glycemic index (LGI) diet",
          "type": "OTHER"
        },
        {
          "name": "high glycemic index (HGI) diet plus placebo (PLAC)",
          "type": "OTHER"
        },
        {
          "name": "high glycemic index diet plus N-acetylcysteine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Seattle Institute for Biomedical and Clinical Research",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 56,
      "start_date": "2011-07",
      "completion_date": "2019-08-01",
      "has_results": true,
      "last_update_posted_date": "2020-08-12",
      "last_synced_at": "2026-10-14T04:54:43.311Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01386645"
    },
    {
      "nct_id": "NCT04918719",
      "title": "Intravenous N-Acetylcysteine for the Treatment of Acute Ischemic Stroke",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Acute Ischemic Stroke"
      ],
      "interventions": [
        {
          "name": "Acetylcysteine",
          "type": "DRUG"
        },
        {
          "name": "Dextrose in Water",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2023-11-02",
      "completion_date": "2024-09-17",
      "has_results": false,
      "last_update_posted_date": "2026-02-19",
      "last_synced_at": "2026-10-14T04:54:43.311Z",
      "location_count": 1,
      "location_summary": "Torrance, California",
      "locations": [
        {
          "city": "Torrance",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04918719"
    },
    {
      "nct_id": "NCT03707951",
      "title": "N-Acetylcysteine for Adolescent Alcohol Use Disorder",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Alcohol Use Disorder"
      ],
      "interventions": [
        {
          "name": "N-acetylcysteine",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral capsule",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical University of South Carolina",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "13 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "13 Years to 25 Years"
      },
      "enrollment_count": 126,
      "start_date": "2019-02-27",
      "completion_date": "2024-02-26",
      "has_results": true,
      "last_update_posted_date": "2025-01-08",
      "last_synced_at": "2026-10-14T04:54:43.311Z",
      "location_count": 1,
      "location_summary": "Charleston, South Carolina",
      "locations": [
        {
          "city": "Charleston",
          "state": "South Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03707951"
    },
    {
      "nct_id": "NCT05664789",
      "title": "Targeting the Neurobiology of RRB in Autism Using N-acetylcysteine: Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Autism Spectrum Disorder"
      ],
      "interventions": [
        {
          "name": "N acetyl cysteine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Stanford University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "3 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "3 Years to 12 Years"
      },
      "enrollment_count": 144,
      "start_date": "2023-04-26",
      "completion_date": "2028-07-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-15",
      "last_synced_at": "2026-10-14T04:54:43.311Z",
      "location_count": 1,
      "location_summary": "Palo Alto, California",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05664789"
    },
    {
      "nct_id": "NCT03822637",
      "title": "The Effect of NAC on Lung Function and CT Mucus Score",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "n-acetylcystine + albuterol",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "0.9% saline + albuterol",
          "type": "COMBINATION_PRODUCT"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT"
      ],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 4,
      "start_date": "2019-02-20",
      "completion_date": "2025-02-21",
      "has_results": true,
      "last_update_posted_date": "2026-06-11",
      "last_synced_at": "2026-10-14T04:54:43.311Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03822637"
    }
  ]
}